3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Melanoma
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
3
Nivolumab
3
Ipilimumab
3
Cyclophosphamide
3
Radiosurgery
2
MART-1 Antigen
2
CTLA-4 Antigen
2
ulixertinib
1
sotrastaurin
1
siremadlin
1
relatlimab
1
pentetreotide
1
oblimersen
1
incomplete Freund's adjuvant
1
fotemustine
1
fludarabine phosphate
1
fludarabine
1
entrectinib
1
defactinib
1
binimetinib
1
benzamide
1
aldesleukin
1
aflibercept
1
Valacyclovir
1
Toll-Like Receptor 1
1
TYRP1 protein, human
1
Sunitinib
1
Standard of Care
1
RO5126766
1
RNA, Messenger
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Uveal Melanoma
×
Toll-Like Receptor 1
×
Clear all
NCT05576077
2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1
Terminated
31 enrolled